U.S. Viral Vaccines CDMO Market (2025 - 2033) Size, Share & Trends Analysis Report By Type (Attenuated Vaccine, Inactivated Vaccine, DNA Vaccines, Subunit Vaccines), By Service, By Workflow, By End-use, By Region, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation and Scope
                    1.2. Market Definitions
                    1.3. Research Methodology
                    1.4. Information Procurement
                        1.4.1. Purchased database
                        1.4.2. GVR’s internal database
                        1.4.3. Secondary sources
                        1.4.4. Primary research
                    1.5. Information or Data Analysis
                        1.5.1. Data analysis models
                    1.6. Market Formulation & Validation
                    1.7. Model Details
                        1.7.1. Commodity flow analysis (Model 1)
                        1.7.2. Value chain based analysis (Model 2)
                        1.7.3. Multivariate Analysis (Model 3)
                    1.8. List of Secondary Sources
                    1.9. List of Primary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Snapshot
                    2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent Market Outlook
                        3.1.2. Related/Ancillary Market Outlook
                    3.2. Market Dynamics
                        3.2.1. Market Driver Analysis
                        3.2.2. Market Restraint Analysis
                    3.3. Technology Landscape
                    3.4. Pricing Model Analysis
                    3.5. Regulatory Framework
                    3.6. Product Pipeline Analysis
                    3.7. Industry Analysis Tools
                        3.7.1. Porter’s Five Forces Analysis
                        3.7.2. PESTEL Analysis
                        3.7.3. COVID-19 Impact Analysis
Chapter 4. U.S. Viral Vaccines CDMO Market: Type Estimates & Trend Analysis
                    4.1. Segment Dashboard
                    4.2. Viral Vaccines CDMO Market: Type Movement Analysis
                    4.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
                    4.4. Attenuated Vaccine
                        4.4.1. Attenuated Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.5. Inactivated Vaccine
                        4.5.1. Inactivated Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.6. DNA Vaccines
                        4.6.1. DNA Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.7. Subunit Vaccines
                        4.7.1. Subunit Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. Viral Vaccines CDMO Market: Service Estimates & Trend Analysis
                    5.1. Segment Dashboard
                    5.2. Viral Vaccines CDMO Market; Service Movement Analysis
                    5.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
                    5.4. Formulation & Process Development
                        5.4.1. Formulation & Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.4.2. Upstream Development
                            5.4.2.1. Upstream Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.4.3. Downstream Development
                            5.4.3.1. Downstream development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.5. Analytical Testing
                        5.5.1. Analytical Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.6. Fill-Finish Services
                        5.6.1. Fill-Finish Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.7. Packaging & Labeling
                        5.7.1. Packaging & Labeling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.8. Others
                        5.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. U.S. Viral Vaccines CDMO Market: Workflow Estimates & Trend Analysis
                    6.1. Segment Dashboard
                    6.2. Viral Vaccines CDMO Market; Workflow Movement Analysis
                    6.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
                    6.4. Clinical
                        6.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.5. Commercial
                        6.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. U.S. Viral Vaccines CDMO Market: End Use Estimates & Trend Analysis
                    7.1. Segment Dashboard
                    7.2. Viral Vaccines CDMO Market; End Use Movement Analysis
                    7.3. Viral Vaccines CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
                    7.4. Biopharmaceutical Companies
                        7.4.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.5. Academic and Research Institutes
                        7.5.1. Academic and Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.6. Others
                        7.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
                    8.1. Company Categorization
                        8.1.1. Market Leaders
                        8.1.2. Emerging Players
                    8.2. Company Market Assessment Analysis, 2024
                    8.3. Company Profiles
                        8.3.1. Lonza
                            8.3.1.1. Company overview
                            8.3.1.2. Financial performance
                            8.3.1.3. Service benchmarking
                            8.3.1.4. Strategic initiatives
                        8.3.2. Catalent, Inc.
                            8.3.2.1. Company overview
                            8.3.2.2. Financial performance
                            8.3.2.3. Service benchmarking
                            8.3.2.4. Strategic initiatives
                        8.3.3. Thermo Fisher Scientific, Inc.
                            8.3.3.1. Company overview
                            8.3.3.2. Financial performance
                            8.3.3.3. Service benchmarking
                            8.3.3.4. Strategic initiatives
                        8.3.4. Fujifilm Diosynth Biotechnologies
                            8.3.4.1. Company overview
                            8.3.4.2. Financial performance
                            8.3.4.3. Service benchmarking
                            8.3.4.4. Strategic initiatives
                        8.3.5. Samsung Biologics
                            8.3.5.1. Company overview
                            8.3.5.2. Financial performance
                            8.3.5.3. Service benchmarking
                            8.3.5.4. Strategic initiatives
                        8.3.6. Emergent BioSolutions
                            8.3.6.1. Company overview
                            8.3.6.2. Financial performance
                            8.3.6.3. Service benchmarking
                            8.3.6.4. Strategic initiatives
                        8.3.7. Recipharm AB.
                            8.3.7.1. Company overview
                            8.3.7.2. Financial performance
                            8.3.7.3. Service benchmarking
                            8.3.7.4. Strategic initiatives
                        8.3.8. Boehringer Ingelheim BioXcellence
                            8.3.8.1. Company overview
                            8.3.8.2. Financial performance
                            8.3.8.3. Service benchmarking
                            8.3.8.4. Strategic initiatives
                        8.3.9. Alcami Corporation
                            8.3.9.1. Company overview
                            8.3.9.2. Financial performance
                            8.3.9.3. Service benchmarking
                            8.3.9.4. Strategic initiatives
                        8.3.10. Vetter Pharma
                            8.3.10.1. Company overview
                            8.3.10.2. Financial performance
                            8.3.10.3. Service benchmarking
                            8.3.10.4. Strategic initiatives

List of Tables

Table 1 List of abbreviations
Table 2 U.S. viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
Table 3 U.S. viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
Table 4 U.S. viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
Table 5 U.S. viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million) 

List of Figures

Fig. 1 U.S. Viral vaccines CDMO market segmentation
Fig. 2 Data analysis models
Fig. 3 Market formulation and validation
Fig. 4 Data validating & publishing
Fig. 5 Market research process
Fig. 6 Information procurement
Fig. 7 Primary research
Fig. 8 Value-chain-based sizing & forecasting
Fig. 9 QFD modelling for market share assessment
Fig. 10 Market formulation & validation
Fig. 11 Commodity flow analysis
Fig. 12 Market outlook
Fig. 13 Segment snapshot 1
Fig. 14 Segment snapshot 2
Fig. 15 Competitive landscape snapshot
Fig. 16 Porter’s five force analysis
Fig. 17 PESTEL analysis
Fig. 18 U.S. Viral vaccines CDMO Market: Type outlook key takeaways
Fig. 19 U.S. Viral vaccines CDMO Market: Type movement analysis
Fig. 20 Attenuated vaccine market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 21 DNA vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 22 Subunit vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 23 U.S. viral vaccines CDMO Market: Services outlook key takeaways
Fig. 24 U.S. viral vaccines CDMO Market: Services movement analysis
Fig. 25 Formulation & process development market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 26 Upstream development market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 27 Downstream development market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 28 Analytical testing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 29 Fill-finish services market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 30 Packaging & labeling market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 31 Others market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 32 U.S. viral vaccines CDMO Market: Workflow outlook key takeaways
Fig. 33 U.S. viral vaccines CDMO Market: Workflow movement analysis
Fig. 34 Clinical market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 35 Commercial market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 36 Biopharmaceutical companies market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 37 Academic and research institutes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 38 Others market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 39 Strategic framework